BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 37175524)

  • 1. Epigenetic Alterations from Barrett's Esophagus to Esophageal Adenocarcinoma.
    Ergun P; Kipcak S; Bor S
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of imaging and biomarkers in diagnosing Barrett's esophagus and predicting the risk of neoplastic progression.
    Ramzan Z; Nassri AB; Huerta S
    Expert Rev Mol Diagn; 2014 Jun; 14(5):575-91. PubMed ID: 24831686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.
    Agarwal A; Polineni R; Hussein Z; Vigoda I; Bhagat TD; Bhattacharyya S; Maitra A; Verma A
    Int J Clin Exp Pathol; 2012; 5(5):382-96. PubMed ID: 22808291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma.
    Kaz AM; Grady WM; Stachler MD; Bass AJ
    Gastroenterol Clin North Am; 2015 Jun; 44(2):473-89. PubMed ID: 26021206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnosis and management of Barrett's esophagus.
    DeMeester SR; DeMeester TR
    Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
    Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
    Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance in Barrett's esophagus: an audit of practice.
    Ajumobi A; Bahjri K; Jackson C; Griffin R
    Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma.
    Wu X; Ajani JA; Gu J; Chang DW; Tan W; Hildebrandt MA; Huang M; Wang KK; Hawk E
    Cancer Prev Res (Phila); 2013 Mar; 6(3):196-205. PubMed ID: 23466817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma.
    Avidan B; Sonnenberg A; Schnell TG; Chejfec G; Metz A; Sontag SJ
    Am J Gastroenterol; 2002 Aug; 97(8):1930-6. PubMed ID: 12190156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.
    Goodarzi M; Correa AM; Ajani JA; Swisher SG; Hofstetter WL; Guha S; Deavers MT; Rashid A; Maru DM
    Mod Pathol; 2009 Dec; 22(12):1612-21. PubMed ID: 19734842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of ultrastructural aberrations with dysplasia and flow cytometric abnormalities in Barrett's epithelium.
    Levine DS; Reid BJ; Haggitt RC; Rubin CE; Rabinovitch PS
    Gastroenterology; 1989 Feb; 96(2 Pt 1):355-67. PubMed ID: 2910757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barrett's surveillance identifies patients with early esophageal adenocarcinoma.
    Wong T; Tian J; Nagar AB
    Am J Med; 2010 May; 123(5):462-7. PubMed ID: 20399324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.
    Brown CS; Lapin B; Wang C; Goldstein JL; Linn JG; Denham W; Haggerty SP; Talamonti MS; Howington JA; Carbray J; Ujiki MB
    Surg Endosc; 2015 Dec; 29(12):3528-34. PubMed ID: 25676204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Esophageal adenocarcinoma arising in cervical inlet patch with synchronous Barrett's esophagus-related dysplasia.
    Tanaka M; Ushiku T; Ikemura M; Shibahara J; Seto Y; Fukayama M
    Pathol Int; 2014 Aug; 64(8):397-401. PubMed ID: 25143128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
    Whitson MJ; Falk GW
    Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Fang HY; Münch NS; Schottelius M; Ingermann J; Liu H; Schauer M; Stangl S; Multhoff G; Steiger K; Gerngroß C; Jesinghaus M; Weichert W; Kühl AA; Sepulveda AR; Wester HJ; Wang TC; Quante M
    Clin Cancer Res; 2018 Mar; 24(5):1048-1061. PubMed ID: 29208671
    [No Abstract]   [Full Text] [Related]  

  • 18. Barrett's esophagus, dysplasia, and adenocarcinoma.
    Haggitt RC
    Hum Pathol; 1994 Oct; 25(10):982-93. PubMed ID: 7927321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysplasia in Barrett's esophagus. A clinicopathologic study of six patients.
    Lee RG
    Am J Surg Pathol; 1985 Dec; 9(12):845-52. PubMed ID: 2416226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression profile and cellular localizations of mucin proteins, CK7, and cytoplasmic p27 in Barrett's esophagus and esophageal adenocarcinoma.
    Ozcan HEA; Anuk T; Ozden O
    Adv Med Sci; 2018 Sep; 63(2):296-300. PubMed ID: 29803118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.